Redeye updates its view on Acarix following its Q1 report. Sales were muted following the implementation of the new business model, which is likely to support an accelerating pace of growth from H2 and onwards. Solid cost control led to better EBIT than we had estimated.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Acarix Q1 2024 - Soft sales but strong outlook

© Modular Finance, source Nordic Press Releases